Arcus Biosciences RCUS
$15.62 −$0.16 (-1.01%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $15.50 -0.77%
Open$15.66
Prev close$15.78
Day range$15.56 – $16.66
Volume1.67M
Market cap$2.25B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$9.00M-65.4% YoY
Operating profit-$131.00M+7.7% YoY
Net profit-$128.00M+5.2% YoY
Diluted EPS-$1.00+21.3% YoY
Free cash flow-$88.00M+9.3% YoY
Operating cash flow-$88.00M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin-475.0%
Net margin-453.0%
Return on equity-114.1%
Return on assets-50.6%
Return on invested capital-93.0%
Current ratio3.34
Liabilities / assets56.2%
Cash & investments$630.00M
Total debt$102.00M
Net cash (debt)$528.00M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $9.00M | $41.00M | $17.00M | $247.00M | $33.00M |
| Total Operating Revenue | $9.00M | $41.00M | $17.00M | $247.00M | $33.00M |
| Operating Expense | $140.00M | $137.00M | $151.00M | $633.00M | $147.00M |
| Selling and Admin Expenses | $23.00M | $24.00M | $29.00M | $110.00M | $26.00M |
| -General & Admin Expense | $23.00M | $24.00M | $29.00M | $110.00M | $26.00M |
| Research & Development | $117.00M | $113.00M | $122.00M | $523.00M | $121.00M |
| Operating Profit | -$131.00M | -$96.00M | -$134.00M | -$386.00M | -$114.00M |
| Net Non-Operating Interest Income (Expense) | $3.00M | $5.00M | $6.00M | $33.00M | $8.00M |
| Non-Operating Interest Income | $6.00M | $8.00M | $9.00M | $41.00M | $10.00M |
| Non-Operating Interest Expense | $3.00M | $3.00M | $3.00M | $8.00M | $2.00M |
| Pretax Profit | -$128.00M | -$91.00M | -$128.00M | -$353.00M | -$106.00M |
| Tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Profit | -$128.00M | -$91.00M | -$128.00M | -$353.00M | -$106.00M |
| Profit from Continuing Operations | -$128.00M | -$91.00M | -$128.00M | -$353.00M | -$106.00M |
| Net Income to Parent Company | -$128.00M | -$91.00M | -$128.00M | -$353.00M | -$106.00M |
| Net Income to Common Stockholders | -$128.00M | -$91.00M | -$128.00M | -$353.00M | -$106.00M |
| Basic EPS | -$1.00 | -$0.72 | -$1.02 | -$3.29 | -$0.89 |
| Diluted EPS | -$1.00 | -$0.72 | -$1.02 | -$3.29 | -$0.89 |
| Special Income (Charges) | – | – | – | $0.00 | $0.00 |
| -Less:Impairment of Capital Assets | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $818.00M | $924.00M | $997.00M | $1.14B | $1.14B |
| Total Current Assets | $664.00M | $756.00M | $844.00M | $1.01B | $1.01B |
| Cash and Cash Equivalents & Short-Term Investments | $630.00M | $702.00M | $822.00M | $981.00M | $981.00M |
| -Cash and Cash Equivalents | $151.00M | $150.00M | $201.00M | $222.00M | $222.00M |
| -Short Term Investments | $479.00M | $552.00M | $621.00M | $759.00M | $759.00M |
| Receivables | $23.00M | $41.00M | $7.00M | $16.00M | $16.00M |
| -Accounts Receivable | $18.00M | $36.00M | $3.00M | $11.00M | $11.00M |
| -Accrued Interest Receivable | $5.00M | $5.00M | $4.00M | $5.00M | $5.00M |
| Other Current Assets | $11.00M | $13.00M | $15.00M | $10.00M | $10.00M |
| Total Non-Current Assets | $154.00M | $168.00M | $153.00M | $132.00M | $132.00M |
| Net PPE | $33.00M | $36.00M | $38.00M | $40.00M | $40.00M |
| -Gross PPE | $33.00M | $36.00M | $38.00M | $90.00M | $90.00M |
| Investments and Advances | $64.00M | $73.00M | $54.00M | $29.00M | $29.00M |
| -Available for Sale Securities | $64.00M | $73.00M | $54.00M | $29.00M | $29.00M |
| Other Non-Current Assets | $57.00M | $59.00M | $61.00M | $63.00M | $63.00M |
| Total Liabilities | $460.00M | $460.00M | $473.00M | $508.00M | $508.00M |
| Total Current Liabilities | $199.00M | $198.00M | $209.00M | $231.00M | $231.00M |
| Payables | $45.00M | $35.00M | $40.00M | $43.00M | $43.00M |
| -Accounts Payable | $44.00M | $34.00M | $39.00M | $42.00M | $42.00M |
| -Total Tax Payable | $1.00M | $1.00M | $1.00M | $1.00M | $1.00M |
| Current Accrued Expenses | $115.00M | $119.00M | $112.00M | $122.00M | $122.00M |
| Short-Term Debt and Capital Lease Obligation | $14.00M | $13.00M | $13.00M | $13.00M | $13.00M |
| -Current Capital Lease Obligation | $14.00M | $13.00M | $13.00M | $13.00M | $13.00M |
| Current Deferred Liabilities | $14.00M | $19.00M | $34.00M | $35.00M | $35.00M |
| Other Current Liabilities | $11.00M | $12.00M | $10.00M | $18.00M | $18.00M |
| Total Non-Current Liabilities | $261.00M | $262.00M | $264.00M | $277.00M | $277.00M |
| Long Term Debt and Capital Lease Obligation | $102.00M | $101.00M | $100.00M | $99.00M | $99.00M |
| -Long Term Debt | $102.00M | $101.00M | $100.00M | $99.00M | $99.00M |
| Non-Current Deferred Liabilities | $34.00M | $37.00M | $45.00M | $43.00M | $43.00M |
| Other Non-Current Liabilities | $125.00M | $124.00M | $119.00M | $135.00M | $135.00M |
| Total Equity | $358.00M | $464.00M | $524.00M | $631.00M | $631.00M |
| Stockholders' Equity | $358.00M | $464.00M | $524.00M | $631.00M | $631.00M |
| Capital Stock | $2.19B | $2.17B | $2.14B | $2.12B | $2.12B |
| -Common Stock | $2.19B | $2.17B | $2.14B | $2.12B | $2.12B |
| Retained Earnings | -$1.83B | -$1.70B | -$1.61B | -$1.49B | -$1.49B |
| Gains/Losses Not Affecting Retained Earnings | -$2.00M | -$1.00M | -$1.00M | – | – |
| -Accumulated Depreciation | – | – | – | -$50.00M | -$50.00M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$88.00M | -$119.00M | -$138.00M | -$482.00M | -$120.00M |
| Net cash flow from continuing operations | -$88.00M | -$119.00M | -$138.00M | -$482.00M | -$120.00M |
| Net Income from Continuing Operations | -$128.00M | -$91.00M | -$128.00M | -$353.00M | -$106.00M |
| Depreciation & Depletion & Amortization | $2.00M | $3.00M | $2.00M | $10.00M | $3.00M |
| Other Non-Cash Items | $3.00M | $4.00M | $2.00M | $8.00M | $1.00M |
| Change in Working Capital | $21.00M | -$47.00M | -$31.00M | -$194.00M | -$30.00M |
| -Change in Receivables | $18.00M | -$3.00M | $8.00M | $9.00M | $0.00 |
| -Change in Payables and Accrued Expense | $10.00M | -$5.00M | -$3.00M | $24.00M | $0.00 |
| -Change in Other Current Assets | $4.00M | $0.00 | -$3.00M | $5.00M | $0.00 |
| -Change in Other Current Liabilities | -$2.00M | -$2.00M | -$16.00M | $8.00M | -$4.00M |
| -Change In Other Working Capital | -$9.00M | -$37.00M | -$17.00M | -$240.00M | -$26.00M |
| Net cash flow from investing | $82.00M | $52.00M | $114.00M | $66.00M | -$182.00M |
| Net Cash Flow from Continuing Investing Activities | $82.00M | $52.00M | $114.00M | $66.00M | -$182.00M |
| Net PPE Purchase and Sale | $0.00 | $0.00 | $0.00 | -$2.00M | -$1.00M |
| Net Investment Purchase and Sale | $82.00M | $52.00M | $114.00M | $68.00M | -$181.00M |
| Financing Cash Flow | $7.00M | $16.00M | $3.00M | $488.00M | $286.00M |
| Net Cash Flow from Continuing Financing Activities | $7.00M | $16.00M | $3.00M | $488.00M | $286.00M |
| Net Issuance Payments Of Debt | $0.00 | – | – | $49.00M | $0.00 |
| Net Common Stock Issuance | $0.00 | $0.00 | $0.00 | $429.00M | $279.00M |
| Proceeds from Stock Option Exercised | $7.00M | $16.00M | $3.00M | $10.00M | $7.00M |
| Ending Cash Balance | $154.00M | $153.00M | $204.00M | $225.00M | $225.00M |
| Net Change in Cash | $1.00M | -$51.00M | -$21.00M | $72.00M | -$16.00M |
| Beginning Cash Balance | $153.00M | $204.00M | $225.00M | $153.00M | $241.00M |
| Free Cash Flow | -$88.00M | -$119.00M | -$138.00M | -$484.00M | -$121.00M |
No comments yet — be the first to weigh in on RCUS.
Sign in to join the discussion.